Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDC00168

Target Information
NameAntiapoptotic protein BCL-XL    
Type of targetClinical trial target    
DiseaseAnaplastic Large Cell Lymphomas
[ICD9: 202.8   ICD10: C81-C96]
Colorectal cancer
[ICD9: 153, 154   ICD10: C18-C21]
[ICD9: 163   ICD10: C45]
Drug(s)ABT-263Phase IIAdvanced small cell lung cancer; Relapsed or refractory chronic lymphocytic leukemia; Relapsed or refractory lymphoid malignancies[4][5][6]
AT-101Phase IILymphoid Leukemia, Non-Hodgkin's Lymphoma, Prostate Cancer[7]
BioChemical ClassTransmembrane protein    
PathwayAmyotrophic lateral sclerosis (ALS)
Chronic myeloid leukemia
Jak-STAT signaling pathway
Pancreatic cancer
Pathways in cancer
Small cell lung cancer
UniProt IDQ07817
PDB Structure1BXL; 1G5J; 1LXL; 1MAZ; 1R2D; 1R2E; 1R2G; 1R2H; 1R2I; 1YSG; 1YSI; 1YSN; 2B48; 2LP8; 2LPC; 2M03; 2M04; 2O1Y; 2O2M; 2O2N; 2P1L; 2PON; 2YJ1; 2YQ6; 2YQ7; 2YXJ; 3CVA; 3FDL; 3FDM; 3INQ; 3IO8; 3PL7; 3QKD; 3R85; 3SP7; 3SPF; 3ZK6; 3ZLN; 3ZLO; 3ZLR; 4A1U; 4A1W; 4AQ3; 4EHR; 4HNJ.    
FunctionPotent inhibitor of cell death. Isoform bcl-x(l) anti- apoptotic activity is inhibited by association with siva isoform 1. Inhibits activation of caspases (by similarity). Appears to regulate cell death by blocking the voltage-dependent anion channnel.    
Target ValidationClick to Find Target Validation Information.    
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood. 2004 Apr 1;103(7):2787-94. Epub 2003 Dec 4. To Reference
Ref 2Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. Mol Cancer Ther. 2004 Feb;3(2):169-78. To Reference
Ref 3Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol. 2001 Nov;25(5):562-8. To Reference
Ref 4Roche. Product Development Pipeline. July 29 2009. To Reference
Ref 5ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008 Oct;7(10):3265-74. To Reference
Ref 6Cancer Res. 2008 May 1;68(9):3421-8.ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. To Reference
Ref 7Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther. 2009 Aug 8;8(16). [Epub ahead of print] To Reference
Ref 8Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543